AR031599A1 - VACCINES FOR VIRUS HERPES EQUINO TYPE 1: VIRUSES THAT HOST MUTATIONS WITHIN THE IMMEDIATE PRECOZ GENE - Google Patents

VACCINES FOR VIRUS HERPES EQUINO TYPE 1: VIRUSES THAT HOST MUTATIONS WITHIN THE IMMEDIATE PRECOZ GENE

Info

Publication number
AR031599A1
AR031599A1 ARP010103602A AR031599A1 AR 031599 A1 AR031599 A1 AR 031599A1 AR P010103602 A ARP010103602 A AR P010103602A AR 031599 A1 AR031599 A1 AR 031599A1
Authority
AR
Argentina
Prior art keywords
immediate
vhe
isolates
hev
gene
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of AR031599A1 publication Critical patent/AR031599A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a los aislados del virus herpes equino tipo 1(VHE-1)mutante, y en particular a los aislados VHE-1 que transportan mutaciones en el gen inmediato-precoz (IP) del genoma viral. Un panel de aislado del VHE-1 mutante se ha descripto en la presente. Los aislados del VHE-1 preferidos son aquellos que son de replicacion-competente y no patogénica. Los aislados del VHE-1 mutante de la presente invencion son utiles para formular composiciones de vacuna para impedir y tratar las infecciones por el VHE-1 en los equinos. Además la presente proporciona los métodos para determinar la patogenicidad de un VHE-1 presente en un equino que ha sido previamente inmunizado con un aislado de VHE-1 no patogénico.It refers to mutant equine herpes virus type 1 (VHE-1) isolates, and in particular to VHE-1 isolates that carry mutations in the immediate-early gene (IP) of the viral genome. An isolate panel of mutant HEV-1 has been described herein. Preferred VHE-1 isolates are those that are replication-competent and non-pathogenic. Isolates of the mutant HEV-1 of the present invention are useful for formulating vaccine compositions to prevent and treat HEV-1 infections in horses. In addition, the present provides methods for determining the pathogenicity of a HEV-1 present in an equine that has previously been immunized with a non-pathogenic VHE-1 isolate.

ARP010103602 2000-07-27 2001-07-27 VACCINES FOR VIRUS HERPES EQUINO TYPE 1: VIRUSES THAT HOST MUTATIONS WITHIN THE IMMEDIATE PRECOZ GENE AR031599A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62674800A 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
AR031599A1 true AR031599A1 (en) 2003-09-24

Family

ID=24511676

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103602 AR031599A1 (en) 2000-07-27 2001-07-27 VACCINES FOR VIRUS HERPES EQUINO TYPE 1: VIRUSES THAT HOST MUTATIONS WITHIN THE IMMEDIATE PRECOZ GENE

Country Status (9)

Country Link
EP (1) EP1317481A2 (en)
JP (1) JP2004512826A (en)
AR (1) AR031599A1 (en)
AU (1) AU2001282997A1 (en)
CA (1) CA2417340A1 (en)
DE (1) DE01961753T1 (en)
MX (1) MXPA03000823A (en)
NZ (1) NZ523772A (en)
WO (1) WO2002009750A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
AR040601A1 (en) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed GM NEGATIVE EHV MUTANTS WITHOUT HETEROLOGICAL ELEMENTS
AU2003251356A1 (en) * 2002-07-26 2004-02-16 Animal Health Trust Viral marker
AU2013235423B2 (en) * 2012-03-20 2017-03-30 Boehringer Ingelheim Animal Health USA Inc. Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof
CN108315487B (en) * 2018-04-16 2021-06-22 福建省农业科学院生物技术研究所 Primer group and kit for detecting eel herpesvirus and application of primer group and kit
CN110885794A (en) * 2019-10-30 2020-03-17 新疆农业大学 Equine herpesvirus type 1 and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
EP0668355B1 (en) * 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection

Also Published As

Publication number Publication date
DE01961753T1 (en) 2004-03-11
JP2004512826A (en) 2004-04-30
CA2417340A1 (en) 2002-02-07
EP1317481A2 (en) 2003-06-11
AU2001282997A1 (en) 2002-02-13
WO2002009750A2 (en) 2002-02-07
MXPA03000823A (en) 2003-09-10
WO2002009750A3 (en) 2003-03-27
NZ523772A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
ES2140418T3 (en) CHEMICAL FLAVIVIRUS AND / OR RESTRICTED GROWTH FLAVIVIRUS.
MX342639B (en) High titer recombinant influenza viruses for vaccines and gene therapy.
PL398576A1 (en) Vaccine preparations, pharmaceutical preparations, attenuated influenza virus, vaccination methods, methods for the prevention of an infectious disease, methods of treatment or prevention of cancers, vaccine compositions and pharmaceutical compositions
NO20025171L (en) DNA transfection system for the production of infectious influenza virus
NL300364I1 (en) Recombinant influenza viruses for vaccines and gene therapy
CR8935A (en) INHIBITORS OF THE RNA POLYMERASE DEPENDENT ON THE RNA OF THE HEPATITIS C VIRUS AND COMPOSITIONS
ES2059370T3 (en) A RECOMBINANT HERPES SIMPLEX VIRUS, VACCINES AND METHODS.
AR038596A1 (en) VIRUS EXPRESSION SYSTEMS FOR REINFORCING RECOMBINANTS AND VACCINES THAT INCLUDE OLD HETEROLOGIES DERIVED FROM METAPNEUMOVIRUS
HUP9903822A2 (en) Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases
PE20030285A1 (en) SINGLE DOSE VACCINATION WITH MYCOPLASMA HYOPNEUMONIAE
ATE309821T1 (en) INFLUENZA VIRUS VACCINE COMPOSITION
ATE526411T1 (en) AVIRULENT IMMUNOGENIC FLAVIVIRUS CHIMERA
Thiry et al. Recombination in the alphaherpesvirus bovine herpesvirus 1
FI3244920T3 (en) Foot-and-mouth disease vaccine
BR0207988A (en) Live attenuated strains of prrs virus
DK1425404T3 (en) Vaccinia MVA-E3L Mutants and Their Use
AR031599A1 (en) VACCINES FOR VIRUS HERPES EQUINO TYPE 1: VIRUSES THAT HOST MUTATIONS WITHIN THE IMMEDIATE PRECOZ GENE
CY1106570T1 (en) STABLE, ATTENUATED MUTANT FORMS OF RABIES VIRUS AND LIVE VACCINES THEREOF
AR019250A1 (en) DAMAGED FORMS OF BOVINE VIRAL DIARREA VIRUS, NUCLEIC ACID MOLECULA, VECTOR, USE, METHOD TO MODIFY THE WILD TYPE VIRAL GENOME, MODIFIED GENOME, VACCINE, METHOD TO DENIM A WILD VIRUS VIRUS
ES2141093T3 (en) EQUINE HERPESVIRUSES (EHV) CONTAINING A foreign DNA, PROCEDURE FOR THEIR OBTAINING AND USE IN VACCINES.
AR040623A1 (en) VACCINE AGAINST THE VIRUS OF THE AFTOSA.
ES2120989T3 (en) RECOMBINANT VIRIC VECTOR OF THE VARICELA-ZOSTER TYPE.
US20200138937A1 (en) Genetically Attenuated Nucleic Acid Vaccine
ES2132330T3 (en) VACCINE FOR THE PROTECTION OF HORSES AGAINST INFECTION WITH THE EQUINE HERPES VIRUS.
PE20001331A1 (en) IDENTIFICATION OF SENV GENOTYPES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal